February 2, 2023
The US Food and Drug Administration approved the first oral treatment for anemia on February 1, specifying that daprodustat (Jesduvroq) was labeled for anemia caused by […]
January 27, 2023
The US Food and Drug Administration approved elacestrant (Orserdu, Stemline Therapeutics, Inc) for postmenopausal women or men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer […]
January 27, 2023
The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for relapsed or refractory mantle cell lymphoma (MCL) after at least two […]
January 26, 2023
The US Food and Drug Administration has approved Abbott’s Proclaim XR spinal cord stimulation (SCS) system for the treatment of patients with diabetic peripheral neuropathy (DPN), […]
January 25, 2023
The US Food and Drug Administration (FDA) has cleared the Tidepool Loop, a mobile application for use with compatible continuous glucose monitors (CGMs) and insulin pumps […]
January 23, 2023
The US Food and Drug Administration (FDA) has approved bexagliflozin (Brenzavvy, TheracosBio) for the treatment of adults with type 2 diabetes. The once-daily 20-mg oral sodium-glucose […]
January 20, 2023
The US Food and Drug Administration (FDA) granted accelerated approval for zanubrutinib (Brukinsa) to treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). […]
January 20, 2023
A combination of HER2-targeted drugs used in breast cancer is now available for use in colorectal cancer. The US Food and Drug Administration (FDA) has granted […]
January 12, 2023
The Food and Drug Administration has approved another Tdap vaccine option for use during pregnancy to protect newborns from whooping cough. The agency on Jan. 9 licensed Adacel […]